Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers ; day:13 ; month:3 ; year:2021 ; pages:1-9
Investigational new drugs ; (13.3.2021), 1-9
- Creator
-
Hou, Ming-Mo
Ho, Ching-Liang
Lin, Hsuan-Yu
Zhu, Yunting
Zhang, Xiaodi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-021-01099-1
- URN
-
urn:nbn:de:101:1-2021050219505150207577
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hou, Ming-Mo
- Ho, Ching-Liang
- Lin, Hsuan-Yu
- Zhu, Yunting
- Zhang, Xiaodi
- SpringerLink (Online service)
Other Objects (12)
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody
Humanized mice
Humanized mice
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody
Humanized mice
Humanized mice
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody
Humanized mice
Humanized mice
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus